Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced its participation in the Chardan Virtual 5th Annual Genetic Medicines Conference, taking place October 4-5, 2021.
PITTSBURGH, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced its participation in the Chardan Virtual 5th Annual Genetic Medicines Conference, taking place October 4-5, 2021. Krish Krishnan, Chairman and CEO at Krystal Biotech, will participate in a fireside chat, and Whitney Ijem, SVP, Strategy & Business Development, will join a panel discussion on the utility of non-traditional viral vectors.
Details for the conference are as follows:
| Chardan Virtual 5th Annual Genetic Medicines Conference | |
| Panel details: | Gene Therapy: The Utility of Viral Vectors Non-Traditional Panel Tuesday, October 5 at 9:30am ET |
| Fireside chat: | Tuesday, October 5 at 11:00am ET |
| Fireside Webcast link: | https://wsw.com/webcast/chard9/krys/1895635; |
To access live webcasts of Krystal’s presentation, please visit the Events & Presentations website page. Replays of webcasts will be available for 30 days following the event.
About Krystal Biotech
Krystal Biotech, Inc. (NASDAQ:KRYS) is a pivotal-stage gene therapy company leveraging its novel, redosable gene therapy platform and in-house manufacturing capabilities to develop therapies to treat serious rare diseases. For more information, please visit http://www.krystalbio.com.
| CONTACTS: | |
| Investors: Whitney Ijem Krystal Biotech wijem@krystalbio.com |
Media: Mary Coyle TellMed Strategies mary.coyle@tmstrat.com |
Source: Krystal Biotech, Inc.
